ARID1A gene mutation
Clinical trials for ARID1A gene mutation explained in plain language.
Never miss a new study
Get alerted when new ARID1A gene mutation trials appear
Sign up with your email to follow new studies for ARID1A gene mutation, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a pill target Hard-to-Treat ovarian cancers?
Disease control Stopped earlyThis early-stage trial is testing an experimental oral drug called NXP800 in people with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, to find the safest dose and schedule, and then to see if the drug shows promise in specif…
Matched conditions: ARID1A GENE MUTATION
Phase 1 • Sponsor: Nuvectis Pharma, Inc. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Cancer drug combo tested for rare gene mutation – but trial stopped early
Disease control Stopped earlyThis study tested two drugs, niraparib and bevacizumab, alone or together, in people with recurrent endometrial or ovarian cancer that has a specific gene change called ARID1A. The goal was to see if the drugs could shrink tumors. However, the trial was stopped early after enroll…
Matched conditions: ARID1A GENE MUTATION
Phase 2 • Sponsor: University of Oklahoma • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Cancer drug shows promise for rare gene mutation, but study halted early
Disease control Stopped earlyThis study tested a drug called tazemetostat in people with advanced solid tumors that have a specific gene change (ARID1A mutation). The drug works by blocking a protein that helps these tumors grow. The study aimed to see if the drug could shrink tumors or stop them from growin…
Matched conditions: ARID1A GENE MUTATION
Phase 2 • Sponsor: Prisma Health-Upstate • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC